| Name | Title | Contact Details |
|---|---|---|
Genny Findlay |
Chief Human Resources Officer | Profile |
Rob Pesceone |
Chief Financial Officer | Profile |
Robert Pesceone |
Deputy Chief Financial Officer & Controller | Profile |
Gary Lawrence |
Chief Financial Officer | Profile |
Paula Dinwiddie |
Director of Human Resources | Profile |
Relievant Medsystems, Inc., a privately held medical device company pioneering the INTRACEPT therapy of nerve ablation within vertebral bodies for the treatment of chronic low back pain (CLBP). The INTRACEPT Intraosseous Nerve Ablation System is a patent-protected, minimally invasive, implant-free therapy that utilizes radiofrequency energy delivered into the vertebral body of the spine to ablate the Basivertebral Nerve (BVN). This nerve, characterized in peer-reviewed literature reporting studies of pain signal transmission and in preclinical and clinical evaluations, is a significant contributor in the transduction of pain arising from degeneration of the vertebral bodies associated with CLBP. The INTRACEPT Intraosseous Nerve Ablation System leverages proprietary instruments and methods to disable this nerve.
Carewell is an e-commerce company that provides home health products with discreet packaging and 24/7 service. They aim to improve the lives of caregivers and their loved ones by offering proactive service, compelling content, and expert-vetted products.
Smart devices and digital support that connect patients to care, with clinically-proven results https://t.co/zoMxznOfwA
American College of Health Care Administrators is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.